Propranolol: Effectiveness and Failure in Infantile Cutaneous Hemangiomas

Area of Science:

• Pediatric Oncology
• Dermatology
• Vascular Anomalies

Background:

• Infantile hemangiomas (IHs) are common childhood tumors.
• Approximately 10% of IH patients experience treatment resistance or complications.
• Traditional treatments include corticosteroids, interferon, vincristine, laser, and surgery.

Purpose of the Study:

• To evaluate the efficacy of propranolol in treating infantile hemangiomas.
• To report on cases of infantile hemangiomas with poor or no response to propranolol.
• To emphasize the need for further research into propranolol treatment failure mechanisms.

Main Methods:

• Retrospective case series of five patients with cutaneous infantile hemangiomas treated between January 2011 and June 2012.
• Clinical observation of treatment response to propranolol.
• Literature review of propranolol treatment outcomes for infantile hemangiomas.

Main Results:

• Three out of five patients showed rapid improvement with propranolol.
• One patient experienced slow but complete resolution.
• One patient did not respond to propranolol treatment.
• Treatment failure in IHs appears more frequent in this series than previously reported.

Conclusions:

• Propranolol is a highly effective first-line treatment for most infantile hemangiomas.
• A subset of patients may not respond to propranolol therapy.
• Further investigation into the mechanisms of propranolol resistance in IHs is warranted.